Therapeutics in Axial Spondyloarthritis: A Review of What Works - SPARTAN 2026 Annual Meeting Proceedings.
Macedo RB · 2026 · Current rheumatology reports
Reading the original? How to read a paper.
What this paper found
A 2026 expert review concludes that TNF, IL-17 and JAK drugs all control symptoms in axial spondyloarthritis, that evidence for slowing spinal damage is strongest for TNF blockers and not yet established for JAK inhibitors, and that structured exercise, in sessions of an hour or less, measurably improves activity, function, pain and fatigue. Obesity predicts worse disease and a weaker response to TNF drugs.
Why this is on the map
Current state-of-play on what each drug class does and does not do, with exercise given equal billing to medication.
On the map under these threads
DOI: 10.1007/s11926-026-01234-y · opens in a new tab. The full paper is on the publisher’s site, not here.
Related papers on the board
Papers sharing one or more threads with this one.
A disease-associated gene desert directs macrophage inflammation through ETS2
Nature
Identified a single 'switch' gene called ETS2, sitting on chromosome 21, that turns immune cells inflammatory across AS, IBD, and several other related diseases. Because no current drug targets ETS2, this points to a treatment direction beyond what's already available with TNF and IL-17 blockers.
Gut microbiota and ankylosing spondylitis: current insights and future challenges
Microbial Cell
Comprehensive review of how gut bacterial imbalance disrupts the IL-23/IL-17 inflammatory pathway and weakens the intestinal barrier in AS. Identifies the lack of standardised methodology and large cohorts as the bottleneck for translating this into treatments.
Dysbiosis of Gut Microbiota in Ankylosing Spondylitis Patients
Dove Medical Press
Confirms that intestinal dysfunction precedes or amplifies systemic inflammation in AS. Frames gut microbiota as the convergence point where genetic, immune, and microbial factors meet.
Current status and emerging trends in biological therapies for ankylosing spondylitis: a bibliometric analysis (2004–2024)
Medicine (LWW)
Bibliometric analysis of biological therapies for AS over 2004-2024. Confirms three pillars, TNF, IL-17, and JAK inhibitors, and a persistent inadequate response in a meaningful subset of patients across all three classes.